Stay updated with breaking news from Poster Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received...
/PRNewswire/ -- The "High Potent Medicines Conference" conference has been added to ResearchAndMarkets.com's offering. Looking and the current market scenario,...
MONTPELLIER, France--(BUSINESS WIRE)--Jan 29, 2024--
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 5, 2024--
At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimensResponses were significantly improved with Abecma and continued to deepen over time with a complete response rate of 44% v...